The IPO provides TRex Bio with approximately 2.5 years of cash runway into H2 2029, funding key catalysts: Phase 1b TRB-061 topline data in mid-2027 and Phase 1 TRB-071 initiation in H1 2027. The bottom-of-range pricing and Lilly's non-binding interest (up to 19.9% post-IPO) suggest measured demand. Monitor the over-allotment exercise and any early lock-up releases for near-term supply dynamics.
Executive Summary
TRex Bio, Inc. has priced its initial public offering of 8,333,334 shares of common stock at $14.00 per share, raising approximately $108.5 million in gross proceeds before underwriting discounts and commissions. The offering was upsized from the preliminary range of $14.00-$16.00 per share and closed at the bottom of that range. Net proceeds of approximately $103.5 million will fund Phase 2 trials for TRB-061 in atopic dermatitis and alopecia areata, a Phase 1 trial for TRB-071, and working capital. The IPO converts all outstanding redeemable convertible preferred stock into common stock and establishes a public market for the company's shares on Nasdaq under the ticker TRXB.
Key Financial Metrics
Key Facts
- IPO priced at $14.00 per share, the bottom of the $14.00-$16.00 preliminary range
- 8,333,334 shares sold by the company; total gross proceeds of $116,666,676
- Net proceeds to the company estimated at $103.5 million (or $119.8 million if underwriters exercise the 1,250,000-share over-allotment option)
- Underwriters include J.P. Morgan, Evercore ISI, Cantor, Stifel, and Wedbush PacGrow
- Shares to be listed on Nasdaq under ticker TRXB; delivery expected October 13, 2026
- Proceeds allocated: ~$90M for TRB-061 Phase 2 trials (AD and AA), ~$10M for TRB-071 Phase 1, remainder for working capital
- Eli Lilly has indicated non-binding interest to purchase shares up to 19.9% of post-IPO outstanding shares
- Post-IPO shares outstanding: 27,445,682 (or 28,695,682 if over-allotment exercised)
- Company had $90.9M in cash, cash equivalents, and marketable securities as of June 30, 2026
- Net loss of $29.3M for the six months ended June 30, 2026; accumulated deficit of $123.6M
Financial Impact
IPO raises $116.7M gross ($108.5M net before expenses); net proceeds of ~$103.5M extend cash runway into H2 2029. Immediate dilution of $7.04 per share for new investors (50.3% dilution from IPO price of $14.00 to pro forma as adjusted net tangible book value of $6.96).
Risk Factors
- Clinical-stage biotech with no approved products; TRB-061 and TRB-071 are early-stage and may fail in trials
- Material weakness in internal controls over financial reporting identified and not yet remediated
- Preclinical safety findings for TRB-061 (monkey deaths in toxicology studies) could lead to clinical holds or exposure caps
- Substantial additional capital needed beyond IPO proceeds to complete development; future dilution likely
- Lilly's non-binding interest is not a firm commitment; actual purchases may be less or none
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (Primary) | 0001193125-26-419203 |
| Document: 0001193125-26-419203-index-headers.html | 0001193125-26-419203 |
| Document: 0001193125-26-419203-index.html | 0001193125-26-419203 |
| Document: 0001193125-26-419203.txt | 0001193125-26-419203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | SC 13G | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.79 (−6.82%) |
Oct 16, 2026 11d ago | SC 13D | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $13.79 (−6.82%) |
Oct 16, 2026 11d ago | SC 13D | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.79 (−1.57%) |
Oct 15, 2026 12d ago | Insider Cluster | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $13.79 (−1.57%) |
Oct 15, 2026 12d ago | SC 13G | $14.16 $14.01 | ▼ −1.06% | ▲ +0.05% | $13.79 (−2.61%) |
Oct 13, 2026 14d ago | Press Release | $13.50 $14.16 | ▲ +4.89% | ▲ +4.60% | $13.79 (+2.15%) |
Oct 9, 2026 18d ago | 424B4 | $14.03 $13.60 | ▼ −3.06% | ▼ −3.05% | $13.79 (−1.71%) |
Oct 9, 2026 18d ago | EFFECT | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $13.79 (−1.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers